Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) - Pipeline Review, H2 2017

Published: Sep, 2017 | Pages: 69 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) - Pipeline Review, H2 2017

Summary

According to the recently published report 'Retinoic Acid Receptor Gamma - Pipeline Review, H2 2017'; Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) pipeline Target constitutes close to 18 molecules. Out of which approximately 18 molecules are developed by Companies. 

Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) - Retinoic acid receptor gamma (RARG) is a nuclear receptor that is encoded by the RARG gene. RARG bind as heterodimers to the target response elements in response to their ligands (all-trans or 9-cis retinoic acid) and regulate gene expression in various biological processes. In the absence or presence of hormone ligand, acts mainly as an activator of gene expression due to weak binding to co-repressors. It is required for limb bud development. 

The report 'Retinoic Acid Receptor Gamma - Pipeline Review, H2 2017' outlays comprehensive information on the Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 3, 6, 1, 7 and 1 respectively. Report covers products from therapy areas Dermatology, Musculoskeletal Disorders, Immunology, Ophthalmology, Respiratory, Gastrointestinal, Genetic Disorders and Oncology which include indications Acne Vulgaris, Bronchopulmonary Dysplasia, Allergies, Autoimmune Disorders, Congenital Ichthyosis, Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva), Fibrosis, Gorlin Syndrome (Basal Cell Nevus Syndrome), Head And Neck Cancer, Inflammatory Bowel Disease, Keratoconjunctivitis sicca (Dry Eye), Multiple Hereditary Exostoses, Psoriasis and Retinopathy Of Prematurity.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG)
- The report reviews Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) targeted therapeutics and enlists all their major and minor projects 
- The report assesses Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) targeted therapeutics

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) - Overview 7
Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) - Therapeutics Development 8
Products under Development by Stage of Development 8
Products under Development by Therapy Area 9
Products under Development by Indication 10
Products under Development by Companies 11
Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) - Therapeutics Assessment 14
Assessment by Mechanism of Action 14
Assessment by Route of Administration 16
Assessment by Molecule Type 18
Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) - Companies Involved in Therapeutics Development 20
3SBio Inc 20
Boehringer Ingelheim GmbH 20
Clementia Pharmaceuticals Inc 20
Galderma SA 21
Lee's Pharmaceutical Holdings Ltd 22
Phosphagenics Ltd 22
Promius Pharma LLC 22
Sol-Gel Technologies Ltd 23
Valeant Pharmaceuticals International Inc 23
Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) - Drug Profiles 25
(adapalene + clindamycin hydrochloride) - Drug Profile 25
Product Description 25
Mechanism Of Action 25
R&D Progress 25
(benzoyl peroxide + tretinoin) - Drug Profile 26
Product Description 26
Mechanism Of Action 26
R&D Progress 26
(clindamycin phosphate + tretinoin) - Drug Profile 27
Product Description 27
Mechanism Of Action 27
R&D Progress 27
adapalene + benzoyl peroxide + clindamycin phosphate - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
alitretinoin - Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
bexarotene + CD1530 - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
palovarotene - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
Small Molecule to Antagonize ROR-Gamma for Autoimmune and Allergic Disorders - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
Small Molecules 1 to Agonize Retinoic Acid Receptor Gamma for Musculoskeletal Disorders - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
Small Molecules to Agonize RARG for Fibrosis - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
Small Molecules to Agonize Retinoic Acid Receptor Gamma for Musculoskeletal Disorders - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
tazarotene - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
tazoretene - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
TPX-6001 + tretinoin - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
tretinoin - Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
tretinoin - Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
trifarotene - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
vitamin A palmitate - Drug Profile 51
Product Description 51
Mechanism Of Action 51
R&D Progress 51
vitamin A palmitate - Drug Profile 52
Product Description 52
Mechanism Of Action 52
R&D Progress 52
Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) - Dormant Products 53
Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) - Discontinued Products 55
Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) - Product Development Milestones 56
Featured News & Press Releases 56
Aug 31, 2017: Clementia Announces Data Presentations at Upcoming Medical Conferences in September 56
Jul 20, 2017: Sol-Gel Announces Positive Phase 2 Clinical Trial Results for TWIN in Patients with Acne Vulgaris 57
Jun 05, 2017: Clementia Pharmaceuticals to Host Symposium at the 8th International Conference on Children's Bone Health 57
Mar 28, 2017: Phase 2 Part A Open Label Extension Trial of Palovarotene for Treatment of Patients with Fibrodysplasia Ossificans Progressiva Continues Positive Trends 58
Oct 14, 2016: Clementia Announces Top-line Results from Phase 2 Trial of Palovarotene for Treatment of Patients with Fibrodysplasia Ossificans Progressiva 59
Aug 08, 2016: Clementia Clinical Program: Opportunity for New Adult and Older Adolescent Subjects to Enroll in Palovarotene Study 60
Jun 13, 2016: Clementia Clinical Program: Next Step in Clementia's Clinical Program for Fibrodysplasia Ossificans Progressiva (FOP) 60
Jun 09, 2016: Galderma Trifarotene Development Program Meets Key Milestone for Lamellar Ichthyosis Orphan Disease 61
Apr 23, 2016: Clementia Pharmaceuticals Joins Global FOP Community in Recognizing Fibrodysplasia Ossificans Progressiva (FOP) Awareness Day 62
Apr 14, 2016: Positive Effects of Palovarotene on Spontaneous Heterotopic Ossification, Mobility, and Skeletal Growth in Mouse Models of FOP Reported in Journal of Bone and Mineral Research 63
Feb 29, 2016: Clementia Announces Last Patient Enrolled in Phase II trial of Palovarotene in Patients with Fibrodysplasia Ossificans Progressiva 64
Jan 21, 2016: GSK informs Basilea that it has elected not to continue its U.S. alitretinoin program 64
Aug 25, 2015: Clementia Pharmaceuticals Expands Ongoing Phase 2 Study to Include Children with Fibrodysplasia Ossificans Progressiva 65
May 28, 2015: Clementia Advances Natural History Study of Patients with Fibrodysplasia Ossificans Progressiva 65
Apr 02, 2015: Clementia Advances Phase 2 Clinical Trial of Palovarotene in Fibrodysplasia Ossificans Progressiva Based on Recommendations from Data Monitoring Committee 66
Appendix 68
Methodology 68
Coverage 68
Secondary Research 68
Primary Research 68
Expert Panel Validation 68
Contact Us 68
Disclaimer 69

List of Tables

Number of Products under Development by Stage of Development, H2 2017 8
Number of Products under Development by Therapy Areas, H2 2017 9
Number of Products under Development by Indication, H2 2017 10
Number of Products under Development by Companies, H2 2017 11
Products under Development by Companies, H2 2017 12
Products under Development by Companies, H2 2017 (Contd..1), H2 2017 13
Number of Products by Stage and Mechanism of Actions, H2 2017 15
Number of Products by Stage and Route of Administration, H2 2017 17
Number of Products by Stage and Molecule Type, H2 2017 19
Pipeline by 3SBio Inc, H2 2017 20
Pipeline by Boehringer Ingelheim GmbH, H2 2017 20
Pipeline by Clementia Pharmaceuticals Inc, H2 2017 21
Pipeline by Galderma SA, H2 2017 21
Pipeline by Lee's Pharmaceutical Holdings Ltd, H2 2017 22
Pipeline by Phosphagenics Ltd, H2 2017 22
Pipeline by Promius Pharma LLC, H2 2017 23
Pipeline by Sol-Gel Technologies Ltd, H2 2017 23
Pipeline by Valeant Pharmaceuticals International Inc, H2 2017 24
Dormant Products, H2 2017 53
Dormant Products, H2 2017 (Contd..1), H2 2017 54
Discontinued Products, H2 2017 55